SP1

Summary

SP1 (Sp1 transcription factor, HGNC:11205) is a protein-coding gene on chromosome 12q13.13, encoding Transcription factor Sp1 (P08047). Transcription factor that can activate or repress transcription in response to physiological and pathological stimuli. It is a selective cancer dependency (DepMap: 12.6% of cell lines).

The protein encoded by this gene is a zinc finger transcription factor that binds to GC-rich motifs of many promoters. The encoded protein is involved in many cellular processes, including cell differentiation, cell growth, apoptosis, immune responses, response to DNA damage, and chromatin remodeling. Post-translational modifications such as phosphorylation, acetylation, glycosylation, and proteolytic processing significantly affect the activity of this protein, which can be an activator or a repressor. Three transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 6667 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 72 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 12.6% of screened cell lines
• Transcription factor: yes — 1,379 downstream targets (CollecTRI)
• MANE Select transcript: NM_138473

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11205
Approved symbol	SP1
Name	Sp1 transcription factor
Location	12q13.13
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000185591
Ensembl biotype	protein_coding
OMIM	189906
Entrez	6667

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000327443, ENST00000426431, ENST00000548560, ENST00000551969, ENST00000854917

RefSeq mRNA: 3 — MANE Select: NM_138473 NM_001251825, NM_003109, NM_138473

CCDS: CCDS44898, CCDS8857

Canonical transcript exons

ENST00000327443 — 6 exons

Exon	Start	End
ENSE00001262751	53409362	53409561
ENSE00001262755	53406585	53406753
ENSE00001300823	53410927	53416446
ENSE00001323424	53382110	53383622
ENSE00002328883	53380176	53380298
ENSE00003476492	53381659	53381813

Expression profiles

Bgee: expression breadth ubiquitous, 264 present calls, max score 97.08.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.2244 / max 325.6449, expressed in 1799 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
125746	7.5020	1724
125750	5.9768	1601
125748	1.2233	821
125745	1.1884	833
125753	0.6000	323
125751	0.2935	116
125752	0.2103	61
125747	0.1756	58
125754	0.0301	6
125749	0.0243	8

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nipple	UBERON:0002030	97.08	gold quality
trabecular bone tissue	UBERON:0002483	94.96	gold quality
skin of hip	UBERON:0001554	94.71	gold quality
colonic epithelium	UBERON:0000397	94.00	gold quality
monocyte	CL:0000576	93.68	gold quality
mammalian vulva	UBERON:0000997	93.56	gold quality
mononuclear cell	CL:0000842	93.28	gold quality
leukocyte	CL:0000738	93.23	gold quality
upper leg skin	UBERON:0004262	93.20	gold quality
mammary duct	UBERON:0001765	92.94	gold quality
cardia of stomach	UBERON:0001162	92.88	gold quality
tonsil	UBERON:0002372	92.50	gold quality
oral cavity	UBERON:0000167	92.45	gold quality
calcaneal tendon	UBERON:0003701	92.17	gold quality
medial globus pallidus	UBERON:0002477	92.10	gold quality
pylorus	UBERON:0001166	92.07	gold quality
jejunal mucosa	UBERON:0000399	91.85	gold quality
secondary oocyte	CL:0000655	91.81	gold quality
pharyngeal mucosa	UBERON:0000355	91.58	gold quality
esophagus mucosa	UBERON:0002469	91.54	gold quality
blood	UBERON:0000178	91.53	gold quality
rectum	UBERON:0001052	91.46	gold quality
urethra	UBERON:0000057	91.35	gold quality
vena cava	UBERON:0004087	91.30	gold quality
gall bladder	UBERON:0002110	91.25	gold quality
renal medulla	UBERON:0000362	91.24	gold quality
tendon	UBERON:0000043	91.10	gold quality
lower esophagus mucosa	UBERON:0035834	90.97	gold quality
superior surface of tongue	UBERON:0007371	90.85	gold quality
tendon of biceps brachii	UBERON:0008188	90.69	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.64
E-GEOD-100618	no	440.50

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1379 targets.

Target	Regulation
A4GALT	Unknown
AACS
ABCA1	Activation
ABCA2	Activation
ABCB1	Activation
ABCB8	Activation
ABCC1	Repression
ABCC2
ABCC3	Activation
ABCC6	Activation
ABCC8	Activation
ABCG1
ABCG2	Unknown
ABL1
ABO
ACACA	Activation
ACACB	Activation
ACAN	Unknown
ACAT1
ACHE	Activation
ACKR1	Activation
ACLY	Repression
ACO1	Unknown
ACP5	Activation
ACSBG1	Unknown
ACSL4	Activation
ACSS1	Activation
ACSS2	Activation
ACTA1	Unknown
ACTA2

JASPAR motifs

Motif	Name	Family
MA0079.1	SP1	Three-zinc finger Kruppel-related
MA0079.2	SP1	Three-zinc finger Kruppel-related
MA0079.3	SP1	Three-zinc finger Kruppel-related
MA0079.4	SP1	Three-zinc finger Kruppel-related
MA0079.5	SP1	Three-zinc finger Kruppel-related

JASPAR matrix evidence (PMIDs): PMID:2192357, PMID:17916232, PMID:22021377

Upstream regulators (CollecTRI, top): AP1, AR, ARNT, ATM, CDX2, CEBPA, CEBPB, CEBPD, CEBPG, E2F4, E2F7, EGR1, ESR1, ESRRA, ETS1, GATA3, HDAC1, HDAC2, HIF1A, HMGA1, IFI16, IRF1, IRF6, JUN, KLF11, LEF1, MAZ, MYB, MYBL2, MYOD1, NFATC1, NFIC, NFKB1, NFKB, NKX2-1, NR3C2, NR5A1, OCLN, PARP1, PAX1

miRNA regulators (miRDB)

320 targeting SP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4682	100.00	68.89	1258

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 12.6% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• role in interferon-gamma mediated suppression of macrophage lipoprotein lipase gene transcription (PMID:11796707)
• role in identifying sterol-indendent regulatory elements in human ATP-binding cassette transporter A1 promoter (PMID:11839742)
• hinge region of the human papillomavirus type 8 E2 protein activates the human p21(WAF1/CIP1) promoter via interaction with Sp1 (PMID:11842244)
• role in regulating growth-promoting gene IEX-1 (PMID:11844788)
• role in regulating 11beta-hydroxysteroid dehydrogenase type 2 promoter (PMID:11850421)
• AP-2 down-regulates transcription of the human SOD2 gene via its interaction with Sp1 within the promoter region. (PMID:11853549)
• The expression of the ABO promoter is influenced by the binding of transcription factor Sp1 or Sp1-like protein(s) in both erythroid and epithelial cell lineages. (PMID:11856466)
• Role of Sp1 and Sp3 in the nutrient-regulated expression of the human asparagine synthetase gene (PMID:11867623)
• Binding of Sp1 to the 5’ end Sp1-I site is critical for maximal activity of the Fc gamma RIIIA promoter Pmed1, which directs NK/T cell-specific expression of heterologous genes. (PMID:11884455)
• Enhancement of binding between the c-Jun-Sp1 complex and the Sp1 oligonucleotide was observed in cells treated with PMA, suggesting the possible interaction of c-Jun-Sp1 with GC-rich binding sites in the 12(S)-lipoxygenase gene promoter. (PMID:11914583)
• huntingtin interacts with Sp1 and TAFII130; transcriptional activity of SP1 and TAFII130 disrupted in early Huntingtin’s Disease (PMID:11988536)
• Sp1 and the ets-related transcription factor complex GABP alpha/beta functionally cooperate to activate the utrophin promoter. (PMID:11997063)
• recruits SV40 capsid proteins to the viral packaging signal, ses (PMID:12021324)
• phosphorylated during late Herpes simplex virus type 1 infection and may contribute to decrease of IE and E gene expression (PMID:12050359)
• demonstrates role of the Sp1 protein in basal and estrogen-induced growth and gene expression in breast cancer (PMID:12052832)
• conclude that E2F proteins and Sp1 play an important role in the control of p18 expression (PMID:12077144)
• Mutation of the progesterone receptor promoter Sp1 site eliminated the effect of hPR activation. Activity was increased by Sp1 overexpression. Dephosphorylated Sp1, abundant in decidual cells, enhances binding to DNA & hPR increasing promoter activity. (PMID:12088866)
• The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-betaI and -delta. (PMID:12105191)
• cooperation with hepatocyte nuclear factor-4 leads to transcriptional activation of the human haem oxygenase-1 gene promoter in a hepatoma cell line (PMID:12133007)
• RAI acts as an efficient inhibitor of HIV-1 gene expression in which both NF-kappaB and Sp1 play major roles. (PMID:12134007)
• role in activating p21(WAF/CIP1) expression accompanying 3,3’-diindolylmethane induced G(1) cell cycle arrest in human breast cancer cells (PMID:12151347)
• Results suggest that Sp1 and Sp3 associate with the hTERT promoter, recruiting HDAC for the localized deacetylation of nucleosomal histones and transcriptional silencing of the hTERT gene in normal human somatic cells (PMID:12151407)
• Sp1 plays a role in regulation of promoter activity and in PKA-mediated expression of mitochondrial serine:pyruvate aminotransferase (PMID:12169688)
• TGF-beta1 inhibition of COL2A1 gene transcription in articular chondrocytes is mediated by an increase of the Sp3/Sp1 ratio and by the repression of Sp1 transactivating effects on that gene (PMID:12186868)
• IGFBP-3 promoter is activated by Trichostatin A-upregulated Sp1 (PMID:12200149)
• Sp1 regulates human reduced folate carrier gene expression (PMID:12228234)
• Sp1 regulates basal endoglin transcription in human and mammalian cells (PMID:12228247)
• role of transcription factors Sp1 and Sp3 in the regulation of telomerase activity and human telomerase reverse transcriptase (hTERT) in Jurkat T cells (PMID:12297462)
• there is a mechanically coupled transcriptional circuit that promotes binding of p38 to Sp1 in the nucleus (PMID:12324467)
• findings underline an essential role of AP-2/Sp1 recognition sites in UVB-mediated VEGF expression by the keratinocyte-derived cell line HaCaT (PMID:12358602)
• role in regulating megakaryocyte-specific glycoprotein VI promoter (PMID:12359731)
• This protein plays a role in the identification of regulatory elements in the human adipose most abundant gene transcript-1(apM-1)promoter. (PMID:12378384)
• Sp1 binds to specific elements of the proximal promoter and interacts with factors bound to distal enhancer elements to govern the hepatic activity of the p21 promoter under basal or inducible conditions. (PMID:12379120)
• Binding of Sp1 to the proximal promoter links constitutive expression of the human uPA Phosphorylation of Sp1 determines the presence in vivo and the functionality of the GC-/GA-rich element of the uPA regulatory region in PC3 cells (PMID:12384434)
• TCL1 oncogene transactivation by Sp1. (PMID:12421830)
• confirms the synergistic transactivating role of NF-YA isoforms and Sp1 for the cystathionine beta synthase 1b promoter (PMID:12427542)
• role in enhancing cyclin D1 promoter activity in conjunction with galectin-3 (PMID:12439750)
• Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires this protein. (PMID:12458222)
• role for Sp1 in the regulation of expression of the angiogenic factor TP in colon cancer WiDr cells (PMID:12466967)
• Alterations in the binding activity of Sp1 transcription factor to the sodium/iodide symporter (NIS) promoter results at least in part in reduced expression and transport of NIS in thyroid tumors. (PMID:12475396)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	sp1	ENSDARG00000088347
		ENSDARG00000113284
mus_musculus	Sp1	ENSMUSG00000001280
rattus_norvegicus	Sp1	ENSRNOG00000014084
drosophila_melanogaster	pad	FBGN0038418
drosophila_melanogaster	Spps	FBGN0039169

Paralogs (3): SP4 (ENSG00000105866), SP2 (ENSG00000167182), SP3 (ENSG00000172845)

Protein

Protein identifiers

Transcription factor Sp1 — P08047 (reviewed: P08047)

All UniProt accessions (3): P08047, H3BUU5, H3BVI2

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that can activate or repress transcription in response to physiological and pathological stimuli. Binds with high affinity to GC-rich motifs and regulates the expression of a large number of genes involved in a variety of processes such as cell growth, apoptosis, differentiation and immune responses. Highly regulated by post-translational modifications (phosphorylations, sumoylation, proteolytic cleavage, glycosylation and acetylation). Also binds the PDGFR-alpha G-box promoter. May have a role in modulating the cellular response to DNA damage. Implicated in chromatin remodeling. Plays an essential role in the regulation of FE65 gene expression. In complex with ATF7IP, maintains telomerase activity in cancer cells by inducing TERT and TERC gene expression. Isoform 3 is a stronger activator of transcription than isoform 1. Positively regulates the transcription of the core clock component BMAL1. Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. Plays a role in protecting cells against oxidative stress following brain injury by regulating the expression of RNF112.

Subunit / interactions. Interacts with ATF7IP, ATF7IP2, BAHD1, POGZ, HCFC1, AATF and PHC2. Interacts with HLTF; the interaction may be required for basal transcriptional activity of HLTF. Interacts (deacetylated form) with EP300; the interaction enhances gene expression. Interacts with HDAC1 and JUN. Interacts with ELF1; the interaction is inhibited by glycosylation of SP1. Interaction with NFYA; the interaction is inhibited by glycosylation of SP1. Interacts with ATF7IP and TBP. Interacts with MEIS2 isoform 4 and PBX1 isoform PBX1a. Interacts with EGR1. Interacts with SMARCA4/BRG1. Interacts with RNF112 in an oxidative stress-regulated manner. Interacts with ZBTB7A; ZBTB7A prevents the binding to GC-rich motifs in promoters and represses the transcriptional activity of SP1. Interacts with DDX3X; this interaction potentiates SP1-induced CDKN1A/WAF1/CIP1 transcription. Interacts with MSX1; the interaction may inhibit MSX1 autoinactivation. (Microbial infection) Interacts with varicella-zoster virus IE62 protein. (Microbial infection) Interacts with SV40 VP2/3 proteins. Interacts with SV40 major capsid protein VP1; this interaction leads to a cooperativity between the 2 proteins in DNA binding. (Microbial infection) Interacts with HIV-1 Vpr; the interaction is inhibited by SP1 O-glycosylation.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Up-regulated in adenocarcinomas of the stomach (at protein level). Isoform 3 is ubiquitously expressed at low levels.

Post-translational modifications. Phosphorylated on multiple serine and threonine residues. Phosphorylation is coupled to ubiquitination, sumoylation and proteolytic processing. Phosphorylation on Ser-59 enhances proteolytic cleavage. Phosphorylation on Ser-7 enhances ubiquitination and protein degradation. Hyperphosphorylation on Ser-101 in response to DNA damage has no effect on transcriptional activity. MAPK1/MAPK3-mediated phosphorylation on Thr-453 and Thr-739 enhances VEGF transcription but, represses FGF2-triggered PDGFR-alpha transcription. Also implicated in the repression of RECK by ERBB2. Hyperphosphorylated on Thr-278 and Thr-739 during mitosis by MAPK8 shielding SP1 from degradation by the ubiquitin-dependent pathway. Phosphorylated in the zinc-finger domain by calmodulin-activated PKCzeta. Phosphorylation on Ser-641 by PKCzeta is critical for TSA-activated LHR gene expression through release of its repressor, p107. Phosphorylation on Thr-668, Ser-670 and Thr-681 is stimulated by angiotensin II via the AT1 receptor inducing increased binding to the PDGF-D promoter. This phosphorylation is increased in injured artey wall. Ser-59 and Thr-681 can both be dephosphorylated by PP2A during cell-cycle interphase. Dephosphorylation on Ser-59 leads to increased chromatin association during interphase and increases the transcriptional activity. On insulin stimulation, sequentially glycosylated and phosphorylated on several C-terminal serine and threonine residues. Acetylated. Acetylation/deacetylation events affect transcriptional activity. Deacetylation leads to an increase in the expression of the 12(s)-lipooxygenase gene through recruitment of p300 to the promoter. Deacetylated by HDAC6 which leads to increased expression of ENG and positive regulation of angiogenesis. Ubiquitinated. Ubiquitination occurs on the C-terminal proteolytically-cleaved peptide and is triggered by phosphorylation. Sumoylated with SUMO1. Sumoylation modulates proteolytic cleavage of the N-terminal repressor domain. Sumoylation levels are attenuated during tumorigenesis. Phosphorylation mediates SP1 desumoylation. Proteolytic cleavage in the N-terminal repressor domain is prevented by sumoylation. The C-terminal cleaved product is susceptible to degradation. O-glycosylated; Contains 8 N-acetylglucosamine side chains. Levels are controlled by insulin and the SP1 phosphorylation states. Insulin-mediated O-glycosylation locates SP1 to the nucleus, where it is sequentially deglycosylated and phosphorylated. O-glycosylation affects transcriptional activity through disrupting the interaction with a number of transcription factors including ELF1 and NFYA. Also inhibits interaction with the HIV1 promoter. Inhibited by peroxisomome proliferator receptor gamma (PPARgamma).

Domain organisation. The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Induction. By insulin.

Miscellaneous. In the hepatoma cell line Hep-G2, SP1 precursor mRNA may undergo homotype trans-splicing leading to the duplication of exons 2 and 3.

Similarity. Belongs to the Sp1 C2H2-type zinc-finger protein family.

Isoforms (3)

UniProt ID	Names	Canonical?
P08047-1	1, Sp1a	yes
P08047-2	2, Sp1b
P08047-3	3, Sp1c

RefSeq proteins (3): NP_001238754, NP_003100, NP_612482* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096

UniProt features (112 total): mutagenesis site 45, modified residue 18, region of interest 10, compositionally biased region 7, glycosylation site 6, strand 4, helix 4, turn 4, zinc finger region 3, cross-link 2, splice variant 2, sequence conflict 2, initiator methionine 1, chain 1, short sequence motif 1, site 1, sequence variant 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
1SP1	SOLUTION NMR
1SP2	SOLUTION NMR
1VA1	SOLUTION NMR
1VA2	SOLUTION NMR
1VA3	SOLUTION NMR
6PV0	SOLUTION NMR
6PV1	SOLUTION NMR
6PV2	SOLUTION NMR
6PV3	SOLUTION NMR
6UCO	SOLUTION NMR
6UCP	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P08047-F1	39.98	0.01

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 63–64 (cleavage)

Post-translational modifications (20): 2, 2, 7, 59, 101, 278, 453, 612, 640, 641, 651, 668, 670, 681, 698, 702, 703, 739, 16, 16

Glycosylation sites (6): 491, 612, 640, 641, 698, 702

Mutagenesis-validated functional residues (45):

Position	Phenotype
7	increase in protein stability. no change in sumoylation.
15	enhanced transcriptional activity.
16	loss of sumoylation. no cleavage and reduced transcriptional activity.
18	loss of sumoylation. increased cleavage and enhanced transcriptional activity.
19	no effect on sumoylation nor on proteolytic cleavage.
36	no effect on phosphorylation on dna damage.
56	no effect on phosphorylation on dna damage.
59	loss of phosphorylation. no effect on activated mapk8-mediated phosphorylation. similar loss of phosphorylation as by de
59	some association with chromatin, increased phosphorylation levels and decreased glycosylation.
73	little effect on activated mapk8-mediated phosphorylation.
81	no effect on phosphorylation on dna damage.
85	no effect on phosphorylation on dna damage.
98	no effect on phosphorylation on dna damage.
101	significant reduction of phosphorylation on dna damage.
101	increase in phosphorylation on dna damage.
117	no effect on activated mapk8-mediated phosphorylation.
220	no effect on dephosphorylation by pp2a.
250	no effect on phosphorylation on dna damage.
278	almost complete abolition of activated mapk8-mediated phosphorylation and 40% reduction in protein levels during mitosis
278	increased protein stability during mitosis; when associated with d-739.
281	no effect on phosphorylation on dna damage.
291	no effect on phosphorylation on dna damage.
296	no effect on phosphorylation on dna damage.
313	no effect on phosphorylation on dna damage.
351	no effect on phosphorylation on dna damage.

Function

Pathways and Gene Ontology

Reactome pathways

45 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
R-HSA-2426168	Activation of gene expression by SREBF (SREBP)
R-HSA-2559585	Oncogene Induced Senescence
R-HSA-6807505	RNA polymerase II transcribes snRNA genes
R-HSA-9018519	Estrogen-dependent gene expression
R-HSA-9735871	SARS-CoV-1 targets host intracellular signalling and regulatory pathways
R-HSA-9762293	Regulation of CDH11 gene transcription
R-HSA-9764790	Positive Regulation of CDH1 Gene Transcription
R-HSA-9818030	NFE2L2 regulating tumorigenic genes
R-HSA-9839394	TGFBR3 expression
R-HSA-1430728	Metabolism
R-HSA-1500931	Cell-Cell communication
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-1655829	Regulation of cholesterol biosynthesis by SREBP (SREBF)
R-HSA-170834	Signaling by TGF-beta Receptor Complex
R-HSA-212436	Generic Transcription Pathway
R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
R-HSA-2262752	Cellular responses to stress
R-HSA-2559583	Cellular Senescence
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-418990	Adherens junctions interactions
R-HSA-421270	Cell-cell junction organization
R-HSA-446728	Cell junction organization
R-HSA-556833	Metabolism of lipids
R-HSA-5663205	Infectious disease
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-8939211	ESR-mediated signaling

MSigDB gene sets: 501 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, MODULE_97, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, REACTOME_SIGNALING_BY_TGF_BETA_RECEPTOR_COMPLEX, PID_TELOMERASE_PATHWAY, PID_HNF3B_PATHWAY, FISCHER_G1_S_CELL_CYCLE, GOBP_POSITIVE_REGULATION_OF_AMIDE_METABOLIC_PROCESS, CMYB_01, GOBP_HOST_MEDIATED_ACTIVATION_OF_VIRAL_TRANSCRIPTION, AAGCCAT_MIR135A_MIR135B, GOBP_POSITIVE_REGULATION_OF_VASCULATURE_DEVELOPMENT, TATTATA_MIR374, MODULE_182, GOBP_MODULATION_OF_PROCESS_OF_ANOTHER_ORGANISM

GO Biological Process (18): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of gene expression (GO:0010628), cellular response to insulin stimulus (GO:0032869), response to hydroperoxide (GO:0033194), cellular response to zinc ion starvation (GO:0034224), positive regulation of blood vessel endothelial cell migration (GO:0043536), host-mediated activation of viral transcription (GO:0043923), positive regulation of angiogenesis (GO:0045766), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), rhythmic process (GO:0048511), cellular response to estrogen stimulus (GO:0071391), positive regulation of amyloid-beta formation (GO:1902004), cellular response to wortmannin (GO:1904568), positive regulation of hydrogen sulfide biosynthetic process (GO:1904828), positive regulation of vascular endothelial cell proliferation (GO:1905564), positive regulation of apoptotic signaling pathway (GO:2001235)

GO Molecular Function (21): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), transcription coregulator binding (GO:0001221), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), double-stranded DNA binding (GO:0003690), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), histone acetyltransferase binding (GO:0035035), identical protein binding (GO:0042802), protein homodimerization activity (GO:0042803), histone deacetylase binding (GO:0042826), bHLH transcription factor binding (GO:0043425), sequence-specific DNA binding (GO:0043565), molecular adaptor activity (GO:0060090), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), sequence-specific double-stranded DNA binding (GO:1990837), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (7): chromatin (GO:0000785), euchromatin (GO:0000791), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), transcription repressor complex (GO:0017053), protein-DNA complex (GO:0032993)

Reactome top-level categories

Rollup of top-16 pathways:

Category	Pathways
RNA Polymerase II Transcription	2
Regulation of lipid metabolism by PPARalpha	1
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	1
Regulation of cholesterol biosynthesis by SREBP (SREBF)	1
Cellular Senescence	1
ESR-mediated signaling	1
SARS-CoV-1-host interactions	1
Regulation of CDH11 Expression and Function	1
Regulation of CDH1 Gene Transcription	1
Nuclear events mediated by NFE2L2	1
Signaling by TGFBR3	1
Metabolism of steroids	1
Signaling by TGFB family members	1
Signaling by TGF-beta Receptor Complex	1
Generic Transcription Pathway	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
cellular anatomical structure	3
DNA-templated transcription	2
regulation of gene expression	2
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	2
transcription cis-regulatory region binding	2
chromatin	2
DNA binding	2
enzyme binding	2
DNA-binding transcription factor binding	2
binding	2
regulation of RNA biosynthetic process	1
gene expression	1
positive regulation of macromolecule biosynthetic process	1
response to insulin	1
cellular response to peptide hormone stimulus	1
response to oxidative stress	1
response to oxygen-containing compound	1
cellular response to starvation	1
response to zinc ion starvation	1
positive regulation of endothelial cell migration	1
blood vessel endothelial cell migration	1
regulation of blood vessel endothelial cell migration	1
host-mediated perturbation of viral transcription	1
host-mediated activation of viral process	1
angiogenesis	1
regulation of angiogenesis	1
positive regulation of vasculature development	1
positive regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
biological_process	1
cellular response to hormone stimulus	1
response to estrogen	1
amyloid-beta formation	1
regulation of amyloid-beta formation	1
positive regulation of amyloid precursor protein catabolic process	1
cellular response to ketone	1
response to wortmannin	1

Protein interactions and networks

STRING

3280 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SP1	ESR1	P03372	979
SP1	EP300	Q09472	969
SP1	TP53	P04637	928
SP1	TBP	P20226	900
SP1	E2F1	Q01094	884
SP1	MYC	P01106	883
SP1	HTT	P42858	849
SP1	CREBBP	Q92793	845
SP1	JUN	P05412	827
SP1	SMAD2	Q15796	791
SP1	EPAS1	Q99814	787
SP1	ESR2	Q92731	786
SP1	HDAC1	Q13547	780
SP1	SMAD3	P84022	774
SP1	HIF1A	Q16665	771

IntAct

213 interactions, top by confidence:

A	B	Type	Score
STAT3		psi-mi:“MI:0914”(association)	0.730
POU2F1	SP1	psi-mi:“MI:0915”(physical association)	0.720
SP1	POU2F1	psi-mi:“MI:0915”(physical association)	0.720
POU2F1	SP1	psi-mi:“MI:0407”(direct interaction)	0.720
SP1	POU2F1	psi-mi:“MI:0407”(direct interaction)	0.720
SP1	HCFC1	psi-mi:“MI:0915”(physical association)	0.680
SP1	STAT3	psi-mi:“MI:0915”(physical association)	0.650
SP1	STAT3	psi-mi:“MI:2364”(proximity)	0.650
SREBF2	SP1	psi-mi:“MI:0915”(physical association)	0.630
SP1	SREBF2	psi-mi:“MI:0915”(physical association)	0.630
SP1		psi-mi:“MI:0407”(direct interaction)	0.600
	SP1	psi-mi:“MI:0914”(association)	0.600
SP1	DLX4	psi-mi:“MI:0915”(physical association)	0.600
DLX4	SP1	psi-mi:“MI:0407”(direct interaction)	0.600
FHL2	SP1	psi-mi:“MI:0407”(direct interaction)	0.590
TP53	SP1	psi-mi:“MI:0915”(physical association)	0.590
SP1	TP53	psi-mi:“MI:0915”(physical association)	0.590
SP1	vp3	psi-mi:“MI:0915”(physical association)	0.590

BioGRID (782): SP3 (Reconstituted Complex), SP1 (Reconstituted Complex), SP1 (Affinity Capture-Western), JUN (Affinity Capture-Western), HIC1 (Co-localization), PIN1 (Affinity Capture-Western), SP1 (Affinity Capture-Western), CDK1 (Affinity Capture-Western), CCNB1 (Affinity Capture-Western), SP1 (Biochemical Activity), SP1 (Biochemical Activity), SP1 (Affinity Capture-RNA), PPARG (Affinity Capture-Western), SP1 (Affinity Capture-Western), SP1 (Affinity Capture-Western)

ESM2 similar proteins: A0JME2, A5D7F6, F8VPZ9, O88873, O89090, P08047, P31367, P52591, P54253, P58929, P70178, P78364, Q01714, Q02086, Q07916, Q08E26, Q13227, Q14863, Q2VPU4, Q3U182, Q5E9U0, Q64028, Q66JY2, Q6AI39, Q6T264, Q7Z3K3, Q8BLM0, Q8BZH4, Q8CHH5, Q8CHP6, Q8IXK0, Q8IZL2, Q8K3Z9, Q8K4J6, Q8N196, Q8N1G0, Q8NDX5, Q8QHL5, Q8VHG2, Q91VX2

Diamond homologs: A5ABV9, O08876, O14901, O70494, O89090, O89091, P08047, P0CG40, P41696, Q01714, Q02446, Q02447, Q0VA40, Q13351, Q22678, Q3SY56, Q5XGT8, Q62445, Q64HY3, Q64HY5, Q6BEB4, Q6NW96, Q6P0J3, Q8BMJ8, Q8IXZ3, Q8K1S5, Q8TDD2, Q8VI67, Q90WR8, Q9ESX2, Q9JHX2, Q9TZ64, A1C6L9, A1DH89, A2QCJ9, B0XSK6, B8NGC8, G4N3L5, K9GKQ6, O14335

SIGNOR signaling

104 interactions.

A	Effect	B	Mechanism
MAPK1	up-regulates	SP1	phosphorylation
MAPK3	up-regulates	SP1	phosphorylation
PRKCZ	up-regulates	SP1	phosphorylation
CDK1	up-regulates	SP1	phosphorylation
ATM	unknown	SP1	phosphorylation
MAPK8	up-regulates	SP1	phosphorylation
SP1	“form complex”	SP1/STAT3	binding
NfKb-p65/p50	up-regulates	SP1	binding
CyclinB/CDK1	up-regulates	SP1	phosphorylation
SP1	“up-regulates activity”	CRX	binding
SP1	“up-regulates quantity by expression”	RHO	“transcriptional regulation”
TFAP4	“up-regulates activity”	SP1	binding
ERK1/2	“up-regulates activity”	SP1	phosphorylation
PPP2CA	“up-regulates activity”	SP1	dephosphorylation
MAPK3	“up-regulates activity”	SP1	phosphorylation
CSNK2A1	“down-regulates activity”	SP1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 109 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Downstream signal transduction	5	22.1×	4e-04
Transcriptional regulation by RUNX3	5	15.8×	1e-03
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	9	15.3×	5e-06
FCGR3A-mediated phagocytosis	7	15.2×	1e-04
Cyclin D associated events in G1	5	13.6×	2e-03
Regulation of PTEN gene transcription	6	12.4×	1e-03
Transcriptional regulation by RUNX1	7	11.9×	4e-04
Regulation of actin dynamics for phagocytic cup formation	5	10.7×	4e-03

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of miRNA transcription	12	34.5×	3e-13
embryonic digit morphogenesis	6	17.9×	1e-04
ephrin receptor signaling pathway	5	17.0×	1e-03
cellular response to hydrogen peroxide	7	16.2×	4e-05
cellular response to transforming growth factor beta stimulus	5	13.7×	3e-03
DNA-templated transcription	5	11.1×	5e-03
BMP signaling pathway	5	9.9×	7e-03
response to hypoxia	8	7.6×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

72 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1012 predictions. Top by Δscore:

Variant	Effect	Δscore
12:53380296:GCG:G	donor_gain	1.0000
12:53381809:GGCAG:G	donor_gain	1.0000
12:53381810:GCAG:G	donor_gain	1.0000
12:53381810:GCAGG:G	donor_gain	1.0000
12:53381811:CAGGT:C	donor_loss	1.0000
12:53381814:G:C	donor_loss	1.0000
12:53381815:T:A	donor_loss	1.0000
12:53382103:C:A	acceptor_gain	1.0000
12:53406577:A:AG	acceptor_gain	1.0000
12:53406581:TCA:T	acceptor_loss	1.0000
12:53406583:A:AG	acceptor_gain	1.0000
12:53406583:A:T	acceptor_loss	1.0000
12:53406583:AG:A	acceptor_gain	1.0000
12:53406583:AGGT:A	acceptor_gain	1.0000
12:53406584:G:A	acceptor_gain	1.0000
12:53406584:G:GG	acceptor_gain	1.0000
12:53406584:GGT:G	acceptor_gain	1.0000
12:53406584:GGTG:G	acceptor_gain	1.0000
12:53406584:GGTGA:G	acceptor_gain	1.0000
12:53406749:GGAAG:G	donor_gain	1.0000
12:53406750:GAAG:G	donor_gain	1.0000
12:53406750:GAAGG:G	donor_gain	1.0000
12:53406751:A:T	donor_gain	1.0000
12:53406751:AAG:A	donor_gain	1.0000
12:53406752:AG:A	donor_gain	1.0000
12:53406752:AGGTG:A	donor_loss	1.0000
12:53406753:GG:G	donor_gain	1.0000
12:53406754:G:GG	donor_gain	1.0000
12:53406754:GTG:G	donor_loss	1.0000
12:53409359:CAG:C	acceptor_loss	1.0000

AlphaMissense

5113 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:53409399:T:A	C628S	1.000
12:53409399:T:C	C628R	1.000
12:53409400:G:A	C628Y	1.000
12:53409400:G:C	C628S	1.000
12:53409401:C:G	C628W	1.000
12:53409414:T:A	C633S	1.000
12:53409414:T:C	C633R	1.000
12:53409415:G:C	C633S	1.000
12:53409445:T:C	L643P	1.000
12:53409453:C:A	H646N	1.000
12:53409453:C:G	H646D	1.000
12:53409455:C:A	H646Q	1.000
12:53409455:C:G	H646Q	1.000
12:53409459:C:A	R648S	1.000
12:53409489:T:C	C658R	1.000
12:53409491:T:G	C658W	1.000
12:53409516:T:C	F667L	1.000
12:53409517:T:C	F667S	1.000
12:53409518:C:A	F667L	1.000
12:53409518:C:G	F667L	1.000
12:53409522:C:A	R669S	1.000
12:53409528:G:C	D671H	1.000
12:53409529:A:T	D671V	1.000
12:53409535:T:C	L673P	1.000
12:53409541:G:T	R675M	1.000
12:53409542:G:C	R675S	1.000
12:53409542:G:T	R675S	1.000
12:53409543:C:A	H676N	1.000
12:53409543:C:G	H676D	1.000
12:53409544:A:C	H676P	1.000

dbSNP variants (sampled 300 via entrez): RS1000039371 (12:53413338 TC>T), RS1000079005 (12:53401949 G>A), RS1000109403 (12:53414741 G>A,T), RS1000111602 (12:53406608 C>T), RS1000141427 (12:53406983 C>G), RS1000250117 (12:53380153 T>A,C,G), RS1000333264 (12:53383681 T>A,G), RS1000363742 (12:53385998 C>G), RS1000464569 (12:53396395 C>T), RS1000548584 (12:53400518 G>A), RS1000646469 (12:53405894 A>G), RS1000690960 (12:53384702 A>C), RS1000861459 (12:53388941 C>T), RS1000907420 (12:53388635 A>G), RS1001066202 (12:53394836 A>G)

Disease associations

OMIM: gene MIM:189906 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST002942_9	Percentage gas trapping	6.000000e-07
GCST004601_163	Red blood cell count	1.000000e-10
GCST004622_118	Reticulocyte count	2.000000e-10
GCST004633_25	Neutrophil percentage of white cells	3.000000e-10
GCST005993_56	Mean corpuscular hemoglobin	3.000000e-15
GCST006011_86	Mean corpuscular volume	3.000000e-15
GCST006153_2	Parkinsonism in frontotemporal lobe dementia	8.000000e-06
GCST006418_11	Progressive supranuclear palsy	4.000000e-07
GCST006418_2	Progressive supranuclear palsy	4.000000e-07
GCST009672_1	Hypospadias (moderate to severe)	4.000000e-09
GCST010243_150	Apolipoprotein B levels	1.000000e-08
GCST90002385_228	High light scatter reticulocyte count	1.000000e-10
GCST90002392_384	Mean corpuscular volume	2.000000e-30
GCST90002397_202	Mean spheric corpuscular volume	1.000000e-40
GCST90002403_450	Red blood cell count	1.000000e-34
GCST90002405_304	Reticulocyte count	3.000000e-18
GCST90002406_336	Reticulocyte fraction of red cells	1.000000e-10

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0007628	gas trapping measurement
EFO:0004305	erythrocyte count
EFO:0007986	reticulocyte count
EFO:0007990	neutrophil percentage of leukocytes
EFO:0004527	mean corpuscular hemoglobin
EFO:0004615	apolipoprotein B measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6103 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 366 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL2105734	SEPANTRONIUM BROMIDE	2	366

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2683511	Efficacy,Metabolism/PK	3	metformin	Diabetes Mellitus
rs784888	Efficacy,Metabolism/PK	3	metformin	Diabetes Mellitus;Type 2

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs784888	AMHR2, SP1	3	2.50	1	metformin
rs2683511	SP1	3	3.50	1	metformin

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.10	IC50	8	nM	SEPANTRONIUM BROMIDE

PubChem BioAssay actives

1 with measured affinity, of 23 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione bromide	2025419: Inhibition of human SP1 transfected in PC-3 cells by renilla luciferase reporter gene assay	ic50	0.0080	uM

CTD chemical–gene interactions

194 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic Trioxide	affects methylation, decreases reaction, increases reaction, affects binding, increases expression (+3 more)	9
Quercetin	affects cotreatment, increases activity, affects reaction, increases expression, decreases expression (+3 more)	8
mithramycin A	decreases expression, decreases reaction, increases activity, affects binding, increases reaction (+1 more)	7
trichostatin A	decreases reaction, increases activity, affects binding, affects cotreatment, increases reaction (+3 more)	6
Resveratrol	decreases acetylation, affects binding, increases reaction, decreases activity, affects localization (+5 more)	6
Doxorubicin	increases phosphorylation, affects activity, affects binding, increases reaction, decreases expression (+3 more)	6
Tretinoin	increases expression, increases reaction, affects binding, increases activity	6
Decitabine	affects binding, affects cotreatment, increases reaction, increases expression	5
Cadmium	decreases reaction, increases reaction, decreases activity, affects reaction, decreases expression (+2 more)	5
Hydrogen Peroxide	increases reaction, decreases expression, decreases reaction, affects expression, affects binding (+3 more)	5
Copper Sulfate	decreases reaction, increases expression, affects binding, decreases activity, decreases expression	5
sodium arsenite	affects binding, increases abundance, increases expression, affects reaction, decreases expression (+1 more)	4
Acetylcysteine	decreases expression, decreases reaction, increases expression	4
Copper	decreases abundance, increases expression, increases reaction, decreases reaction, affects abundance (+1 more)	4
Estradiol	affects cotreatment, increases expression, affects binding, increases reaction, decreases expression (+2 more)	4
Plicamycin	affects binding, decreases reaction, increases expression, decreases activity	4
nickel chloride	affects binding, affects cotreatment, increases reaction, increases expression, decreases reaction (+2 more)	3
cordycepin	affects metabolic processing, affects binding, decreases reaction, decreases expression, increases activity	3
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	affects cotreatment, decreases expression, affects binding, decreases reaction, increases reaction (+1 more)	3
U 0126	decreases expression, increases reaction, decreases reaction, increases expression, increases activity	3
Camptothecin	increases expression, affects localization, increases activity, affects reaction, decreases reaction	3
Metformin	decreases reaction, increases expression, decreases expression, affects binding, affects cotreatment (+1 more)	3
Tetrachlorodibenzodioxin	affects binding, increases reaction, increases expression, decreases reaction, increases phosphorylation	3
Tetradecanoylphorbol Acetate	affects localization, affects binding, increases reaction, increases expression, increases activity (+1 more)	3
Valproic Acid	affects binding, increases reaction, decreases expression	3
bisphenol A	increases expression, affects cotreatment	2
deoxynivalenol	affects expression, affects binding, increases reaction, increases phosphorylation, increases expression	2
indole-3-carbinol	affects binding, decreases reaction, decreases activity	2
tetrathiomolybdate	affects binding, increases reaction, decreases abundance, increases expression, increases activity	2
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases expression, decreases reaction	2

ChEMBL screening assays

10 unique, capped per target: 8 binding, 2 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1058704	Binding	Inhibition of SP1-dependent luciferase expression	Scuteflorins A and B, dihydropyranocoumarins from Scutellaria lateriflora. — J Nat Prod
CHEMBL3061786	ADMET	Inhibition of Sp1 (unknown origin) by luciferase reporter gene assay	Synthesis and biological activity of hydrazidehydrazones and their corresponding 3-acetyl-2,5-disubstituted-2,3-dihydro-1,3,4-oxadiazoles — Med Chem Res

Cellosaurus cell lines

9 cell lines: 8 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2H3	Abcam HeLa SP1 KO	Cancer cell line	Female
CVCL_B8Q1	Abcam HCT 116 SP1 KO	Cancer cell line	Male
CVCL_B9BS	Abcam MCF-7 SP1 KO	Cancer cell line	Female
CVCL_B9SH	Abcam A-549 SP1 KO	Cancer cell line	Male
CVCL_D8BB	Ubigene A-549 SP1 KO	Cancer cell line	Male
CVCL_D8W2	Ubigene HCT 116 SP1 KO	Cancer cell line	Male
CVCL_D9ST	Ubigene HEK293 SP1 KO	Transformed cell line	Female
CVCL_E0PS	Ubigene HeLa SP1 KO	Cancer cell line	Female
CVCL_TQ04	HAP1 SP1 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.